Clinical Trial Update: A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002) [Phase 1]

View source ↗

Summary

A Phase I safety and immunogenicity trial of an HIV-1 Tat and V2-deleted Env vaccine (ISS P-002) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• ISS P-002 HIV vaccine

Snippet

Sponsor: Barbara Ensoli, MD | Conditions: HIV Infection | Phase 1 | Status: TERMINATED